Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOOMS
2024-513193-22-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Relapse-free status at 96 weeks and MRI new/enlarging T2 lesion-free status at 96 weeks. Planned start Sep 2024; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-513193-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513193-22-00.